Free Trial
NASDAQ:ELTX

Elicio Therapeutics Q4 2024 Earnings Report

Elicio Therapeutics logo
$14.85 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$14.64 -0.22 (-1.45%)
As of 06/12/2026 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elicio Therapeutics EPS Results

Actual EPS
-$1.02
Consensus EPS
-$0.94
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Elicio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elicio Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Elicio Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules

Elicio Therapeutics Earnings Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More Elicio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

View Elicio Therapeutics Profile